Company Name
Cash Bids
Market Data
News
Ag Commentary
Weather
Resources
|
Merck & Co. Earnings Preview: What to Expect![]() Rahway, New Jersey-based Merck & Co., Inc. (MRK) provides health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. With a market cap of $214.8 billion, Merck operates through Pharmaceutical, Animal Health, and Other segments and serves in nearly 140 countries across the globe. The healthcare giant is gearing up to unveil its third-quarter results before the market opens on Thursday, Oct. 30. Ahead of the event, analysts expect MRK to deliver a profit of $2.37 per share, up 51% from $1.57 per share reported in the year-ago quarter. Further, the company has a solid earnings surprise history and has surpassed the Street’s bottom-line estimates in each of the past four quarters. For the full fiscal 2025, analysts expect MRK to deliver an EPS of $8.94, up 16.9% from $7.65 reported in 2024. While in fiscal 2026, its earnings are expected to grow 5.8% year-over-year to $9.46 per share. ![]() MRK stock prices have plummeted 21.9% over the past 52 weeks, notably underperforming the Health Care Select Sector SPDR Fund’s (XLV) 7.8% decline and the S&P 500 Index’s ($SPX) 14.4% gains during the same time frame. ![]() Merck’s stock prices dipped 1.7% in the trading session following the release of its mixed Q2 results on Jul. 29. The company’s KEYTRUDA sales grew by 9% to $8 billion, while Animal Health Sales surged by 11% to $1.6 billion, but its GARDASIL sales plummeted 55% year-over-year to $1.1 billion. Overall, the company’s topline came in at $15.8 billion, down 1.9% year-over-year and missing the Street’s expectations by a small margin. Meanwhile, its adjusted EPS dropped 6.6% compared to the year-ago quarter to $2.13, but surpassed the consensus estimates by 6%. Analysts take an optimistic view of the stock’s prospects. MRK maintains a consensus “Moderate Buy” rating overall. Of the 25 analysts covering the stock, opinions include 11 “Strong Buys,” one “Moderate Buy,” and 13 “Holds.” Its mean price target of $102.43 suggests a 19.5% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. |
|